Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
53 Leser
Artikel bewerten:
(0)

Sunpeaks Ventures Announces Agreement with Albeck Financial Services

SILVER SPRING, Md., April 3, 2012 /PRNewswire/ --Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that the Company has entered into an Agreement with Albeck Financial Services Inc. ("Albeck"). Under terms of the Agreement, Albeck will provide outsourced Chief Financial Officer services, pre-audit support, financial reporting, and advisory services to Sunpeaks and its subsidiaries.

"We are very excited to have Albeck join our growing team," said Mackie A Barch, CEO of Sunpeaks. "To have agroup of seasoned professionals like Albeck involved with planning and executing our financial strategy is absolutely critical because it will allow the current Sunpeaks management group to focus on continually expanding the core business of the Company."

About Albeck Financial Services Inc.

With over 20 years of niche-focused accounting and consulting experience, Albeck delivers unparalleled expertise in pre-audit, financial reporting, SOX compliance, and non-routine financial functions to publicly traded micro-cap to mid-cap size corporations, as well as to privately held entities clients, both domestic and international.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.